Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.
ZIVO Bioscience, Inc. (ZIVO) generates news primarily through its biotech and agtech research and development activities focused on algae-derived product candidates for human and animal health. Company updates frequently highlight progress in poultry health, including studies targeting coccidiosis and Low Pathogenicity Avian Influenza (LPAI) in broiler chickens, as well as developments in human nutrition applications based on antioxidant-rich algal materials.
News items often cover results from controlled challenge and confirmatory studies conducted with academic institutions such as the University of Delaware and with major global animal health companies. These releases describe endpoints like intestinal lesion scores, feed conversion ratio, viral titers and disease transmission dynamics, and explain how ZIVO’s proprietary active ingredients perform as non-antibiotic, immune-modulating interventions in poultry production settings.
Investors and industry observers can also find announcements about collaborations, licensing discussions and funded research agreements with leading animal health companies. These stories provide insight into how ZIVO is pursuing potential exclusive licenses for its coccidiosis treatment candidate and expanding the evaluation of its immune-enhancing compounds as biologics that may complement existing vaccination strategies.
In addition, ZIVO issues communications on its human nutrition initiatives, including shareholder letters that discuss independent biochemical analyses of its algae and positioning in the nutraceutical marketplace. Corporate updates, such as participation in investor conferences and changes in financial leadership reported through SEC filings, also appear in the news flow. Bookmark this page to follow ZIVO’s latest study results, partnership developments and corporate announcements as the company advances its algae-based pipeline.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced significant progress in their financial and product development in a recent shareholder letter. The company successfully completed a capital raise of $12.2 million after its Nasdaq up-listing, enhancing its financial resources for R&D in biotech and agtech. Ongoing studies in poultry gut health and algal biomass applications are underway, indicating a commitment to innovation. They are also expanding operations in multiple locations, addressing COVID-related delays, and exploring new product potentials in health markets.
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech company, announced that CEO Andrew Dahl will present at two upcoming virtual investor conferences. He will speak at the Q3 Investor Summit on August 17, 2021, at 9:30 am ET, and at the SNN Network Summer Virtual Event on August 19, 2021, also at 9:30 am ET. Management will be available for one-on-one meetings during both events. Investors can register through the provided links. Zivo focuses on developing therapeutic and nutritional products from proprietary algal cultures for health benefits.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced the closing of the sale of an additional 150,000 shares of common stock at $4.99 per share, generating gross proceeds of approximately $748,500. This follows the partial exercise of the underwriters’ over-allotment option related to its public offering that closed on June 2, 2021. The offering was managed by Maxim Group LLC and Joseph Gunnar & Co., LLC. The shares were sold under the registration statements filed with the SEC. Zivo specializes in developing bioactive compounds derived from proprietary algal cultures for medicinal and nutritional applications.
ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a Michigan-based biotech/agtech firm, will be presenting at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Andrew Dahl is scheduled to deliver a corporate overview on June 9 at 6:00 PM ET, Track 3. Investors can register to view the presentation online. ZIVO focuses on developing therapeutic and nutritional bioproducts from proprietary algal cultures, targeting immune health and functional food ingredients. The company's products aim to enhance immune response and reduce contamination in poultry.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced the closing of its public offering of 2,760,000 units at $5.00 each, generating approximately $13.8 million in gross proceeds. Each unit includes one share of common stock and one warrant priced at $5.50. Following a 1-for-80 reverse stock split effective May 28, 2021, the common stock and warrants trade separately on Nasdaq. Additionally, underwriters have a 45-day option to purchase up to 414,000 shares and/or warrants.
Zivo Bioscience, Inc. (OTCMKTS:ZIVO) announced an upsized public offering of 2,760,000 units priced at $5.00 per unit, expected to generate $13.8 million before expenses. Each unit comprises one share of common stock and one warrant, with the warrants exercisable at $5.50. The offering will close on June 2, 2021, and follows a 1-for-80 reverse stock split effective May 28, 2021. ZIVO has granted underwriters a 45-day option to purchase additional units for over-allotments. Trading on Nasdaq is set to commence on May 28, 2021.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) announced a Notice of Allowance for a patent on its algal biomass product aimed at promoting immune health in dairy cattle. This development stems from extensive in vitro studies showcasing the product's benefits. The company plans follow-on patents for other animal species and human applications. ZIVO's research indicates improvements in immune health in animals when its products are used in feed, with potential effectiveness in addressing joint stiffness for humans as well. The company positions itself in the growing nutraceutical market.
KEEGO HARBOR, Mich., March 11, 2021 – ZIVO Bioscience (OTCQB: ZIVO) announced that CEO Andrew A. Dahl will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can view his corporate presentation post-registration and request one-on-one meetings. ZIVO focuses on R&D of therapeutic products derived from proprietary algal cultures aimed at health benefits, particularly for autoimmune and inflammatory responses. Forward-looking statements highlight risks and uncertainties around product commercialization and market acceptance.